Pipeline
Our Pipeline
Our broad pipeline includes multiple targeted therapies that harness the immune system and target specific molecular pathways.
Global, excluding China, Hong Kong, and Macau
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Approved in China
Global Phase 2 SPARTA
Met Exon 14 NSCLC
APL-101 (Vebreltinib)
Global, excluding China, Hong Kong, and Macau
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Approved in China
Global Phase 2 SPARTA
Met amplified NSCLC
APL-101 (Vebreltinib)
Global, excluding China, Hong Kong, and Macau
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Approved in China
Global Phase 2 SPARTA
Met fusion GBM
APL-101 (Vebreltinib)
Global
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Solid tumors
APL-102
Global, excluding China
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Phase 1 Dose Escalation Study
Solid tumors
APL-501
Global, excluding China
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Approved in China
Ex-China in Development
Multiple tumor types
APL-502
Global
NDA
P.3
P.2
P.1
IND
Preclinic.
Discov.
Multiple tumor types
APL-801